Some epilepsy medications cause significant weight gain, but most are considered weight-neutral. The effect depends almost entirely on which specific drug you’re taking. A few medications are even linked to weight loss. If you’ve noticed the number on the scale climbing since starting treatment, your medication may be the reason, but there are practical options worth discussing with your prescriber.
Which Medications Cause Weight Gain
The epilepsy drugs most consistently linked to weight gain are valproic acid (Depakote), gabapentin (Neurontin), and pregabalin (Lyrica). Vigabatrin also falls into this category. Carbamazepine sits in a gray area: some studies show modest weight gain, while others find it has no meaningful effect.
Valproic acid is the most studied offender. In clinical trials, patients on valproic acid showed significant weight gain as early as 10 weeks after starting treatment, and weight continued climbing throughout the study period with no sign of leveling off. Research tracking patients for four or more years found the upward trend persisted the entire time. That’s unusual compared to many drug side effects, which tend to stabilize after a few months.
Gabapentin has been associated with an average gain of about 2.2 kilograms (roughly 5 pounds) in just six weeks, based on a systematic review. Higher doses produce more weight gain. In clinical trials of patients taking 2,400 mg or 3,600 mg daily, participants gained 1.2 to 1.8 kilograms over 14 weeks. Pregabalin follows a similar pattern: in one large trial, 11.4% of patients on pregabalin gained at least 7% of their body weight, compared to just 3.1% on placebo.
Which Medications Are Weight-Neutral or Cause Weight Loss
Several commonly prescribed epilepsy drugs have little to no effect on weight. Lamotrigine (Lamictal), levetiracetam (Keppra), and phenytoin (Dilantin) are all considered weight-neutral. In an eight-month study comparing lamotrigine to valproic acid, patients on lamotrigine maintained a stable weight the entire time while those on valproic acid gained steadily. Oxcarbazepine, lacosamide, and eslicarbazepine are also in the weight-neutral category.
Topiramate (Topamax) and zonisamide (Zonegran) tend to cause weight loss rather than gain. Felbamate has a similar effect. These drugs reduce appetite in many people, which is why topiramate is also approved as part of a combination weight-loss medication. For someone concerned about weight gain, these options sit at the opposite end of the spectrum.
Why These Drugs Affect Weight
The exact mechanisms aren’t fully understood, but the best evidence points to changes in insulin and blood sugar regulation. Valproic acid appears to stimulate the pancreas to release more insulin, which increases appetite and encourages the body to store energy as fat. Patients who gain weight on valproic acid tend to have higher circulating insulin levels than those who don’t, suggesting a form of insulin resistance plays a role.
Valproic acid also lowers blood sugar levels and may increase levels of a gut hormone called GLP-1, which is involved in glucose regulation. What’s less clear is whether the drug directly changes metabolism or whether it primarily drives people to eat more. One controlled trial found that patients on valproic acid appeared to increase their food intake in the first few weeks of treatment, then tried to cut back by day 21, suggesting the early weight gain is at least partly driven by increased appetite rather than a slower metabolism.
For gabapentin and pregabalin, the mechanism is even less well defined, but increased appetite and fluid retention both seem to contribute.
Women Are Affected More Than Men
Weight gain on valproic acid is not equally distributed between genders. In a study comparing men and women on the drug, both groups gained significant weight, but women gained more frequently and more severely. About 26% of women on valproic acid reported intense carbohydrate cravings, compared to 14% of men. Women also had higher levels of leptin, a hormone that normally signals fullness, suggesting they may develop a form of leptin resistance where the brain stops responding to the “stop eating” signal.
This gender difference matters especially for women of childbearing age, who are already advised to use valproic acid cautiously due to risks during pregnancy. The added burden of weight gain, and the psychological stress that comes with it, makes this a medication worth reconsidering for many women if effective alternatives exist.
Weight Changes in Children
Children on epilepsy medication face unique concerns because weight changes can interfere with normal growth patterns. Valproic acid is, again, the drug most strongly associated with increased appetite and weight gain in pediatric patients. Pregabalin and perampanel may also cause modest weight gain in children.
On the other hand, several medications that are weight-neutral in adults also appear safe for children’s growth trajectories. Lamotrigine, levetiracetam, oxcarbazepine, carbamazepine, lacosamide, and clobazam all show minimal impact on appetite or weight in pediatric studies. Topiramate, zonisamide, and cannabidiol are among those linked to decreased appetite in children, which can be its own concern if a child is underweight or growing rapidly.
Managing Weight Gain on Epilepsy Drugs
The most effective strategy is switching to a medication with a lower weight-gain profile, when seizure control allows for it. Moving from valproic acid to lamotrigine, for example, removes the primary driver of weight gain while using a drug that keeps weight stable. This kind of switch requires careful planning since changing epilepsy medications carries a risk of breakthrough seizures, but it’s a conversation worth having if weight gain is significantly affecting your quality of life or health.
If switching isn’t possible because your current medication is the only one controlling your seizures well, lifestyle changes can help offset some of the gain. Research on drug-induced weight gain across medication classes suggests that reducing daily calorie intake by 500 to 1,000 calories and aiming for about 150 minutes of moderate exercise per week can meaningfully slow or reduce weight gain. Starting these habits early, ideally when you first begin a medication known to cause weight gain, is more effective than trying to reverse gains later. Some evidence also suggests that combining lifestyle changes with blood-sugar-regulating treatments can be more effective than either approach alone.
Monitoring your weight from the very start of treatment gives you and your prescriber useful data. Since valproic acid can cause noticeable gain within the first 10 weeks and doesn’t plateau on its own, catching the trend early opens up more options than waiting until 20 or 30 pounds have accumulated.